Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363815 | 0.76 | KCNA5 (0.58) | ALDH1A1 | |
| SCHEMBL3928724 | 0.74 | KCNA5 (0.55) | — | |
| SCHEMBL3753839 | 0.74 | GAA (0.58) | TSHRALDH1A1GAA | |
| SCHEMBL4371240 | 0.74 | KCNA5 (0.70) | — | |
| SCHEMBL3936466 | 0.72 | SCN9A (0.60) | ALDH1A1 | |
| SCHEMBL3934300 | 0.71 | ALDH1A1 (0.54) | TSHRALDH1A1NPSR1 | |
| SCHEMBL3929161 | 0.71 | MEN1 (0.39) | TSHRGAANPSR1 | |
| SCHEMBL3929089 | 0.70 | THRB (0.66) | TSHRALDH1A1NPSR1 | |
| SCHEMBL3928927 | 0.70 | KCNA5 (0.69) | TSHRALDH1A1 | |
| SCHEMBL4007068 | 0.69 | THRB (0.51) | TSHRALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291983-A1 | 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | US | claimed |
| EP-2044019-A1 | 3-OXOISOINDOLINE-1-CARBOXAMIDE DERIVATIVES AS ANALGESIC AGENTS | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | claimed |
| WO-2008008020-A1 | 3-OXOISOINDOLINE-1-CARBOXAMIDE DERIVATIVES AS ANALGESIC AGENTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | claimed |
| US-20090291983-A1 | 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291983-A1 | 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents | OPRD1, OPRK1, OPRM1 | TSHR 1560/4885RAB9A 2829/4885ALDH1A1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.